Src酪氨酸激酶抑制剂M475271对非小细胞肺癌的抑制作用及其抑制机理的研究
|
摘要
肺癌是世界范围肿瘤相关性死亡的主要病因,发病率和病死率逐年上升,其中80%以上表现为非小细胞肺癌(NSCLC)。早期非小细胞肺癌可以手术切除治疗,但是当大多数患者被诊断出非小细胞肺癌时,都已处于中晚期,伴有局部或远隔脏器转移,已经不适合手术治疗。虽然全身化疗可以降低中晚期非小细胞肺癌的病死率,但通常来说非小细胞肺癌对传统的化疗并不敏感,而且由于化疗药物剂量依赖的毒性反应也限制了其应用,因此中晚期非小细胞肺癌预后不好。
近年来非小细胞肺癌药物治疗的新策略转向抑制肿瘤生长进展中特异性通路和关键分子的分子靶向治疗。其中,表皮生长因子受体(EGFR)酪氨酸激酶抑制剂已成功地用于治疗某些晚期非小细胞肺癌。相对于鳞癌,EGFR酪氨酸激酶抑制剂对于腺癌更有效,然而也只是部分腺癌患者有临床反应。因此,有必要加强对其它重要的靶分子的研究。
Src是最早报道的癌基因,作为原型与后来发现的其它癌基因有着共同的特点。反转录病毒基因V-Src具有致癌性,其同源的原癌基因C-Src是人或动物细胞中的正常基因,它们编码分子量为60kD的非受体蛋白酪氨酸激酶。Src蛋白在调控细胞的生长(生存和增生)、黏附、运动和细胞信号转导等方面发挥重要作用。人类很多肿瘤,例如结肠癌、乳腺癌和胰腺癌,都存在Src蛋白的过度表达和/或活化,Src在肿瘤的发生、发展和转移中具有重要作用。近年来有人发现,与正常肺组织相比,半数肺癌中C-Src蛋白的表达增高,小细胞肺癌C-Src激酶活性较低,非小细胞肺癌,特别是腺癌中,C-Src激酶活性明显增高。随着腺癌肿块的增大,C-Src激酶活性也增高,与腺癌的进展相关。低分化鳞癌中C-Src蛋白的表达明显高于中高分化的鳞癌。C-Src蛋白在非小细胞肺癌中的高表达和高活化,提示Src可以
IntroductionNon-small cell lung cancer ( NSCLC) accounts for about 80% of all lung cancers. Although some progress has been made in the treatment of NSCLC, NSCLC remains the leading cause of cancer-related mortality in most countries. The majority of the diagnosed patients with NSCLC are in advanced stage because of its highly metastatic properties, and such patients are not candidates for surgical resection. Although systemic chemotherapy reduces the rate of death attributable to advanced NSCLC, disease progression is inevitable and dose-limiting toxicities restrict its use.A novel strategy for chemorefractory NSCLC in advanced stage is molecular-ly targeted therapy inhibiting specific pathways and key molecules implicated in tumor growth and progression. Among molecularly targeted therapies, inhibitors of epidermal growth factor receptor (EGFR) -tyrosine kinases have been successfully developed for advanced NSCLC. Although EGFR inhibitors are more effective for adenocarcinoma compared with squamous cell carcinoma, the clinical responses are observed only in some populations of the patients even in adenocarcinoma. Therefore, novel drugs targeting other critical molecules are required for patients with NSCLC.Src is the first reported oncogene and has been a prototype in identifying many characteristics of follow on oncogenes. C-Src and its retroviral form ( V-Src) are both non-receptor tyrosine kinases, encoding a Mr 60,000 membrane -associated protein tyrosine kinase ( PTK). Results from many different studies suggest a role of Src in various aspects of a cell's life, including proliferation,
survival, motility, cell-cell and cell - matrix adhesion, and local invasion, all of which are deregulated during cancer progression. C-Src has been found to be over-expressed and highly activated in a variety of human cancers, including colon cancer, breast cancer, and pancreatic cancer. Recent studies showed that the proto-oncogene C-Src was also highly activated in NSCLC, especially in ade-nocarcinomas, suggesting the possibility of molecular targeted therapy for lung adenocarcinoma.M475271 is a novel, orally available selective inhibitor of Src kinases. It has potential to inhibit migration of the highly metastatic human pancreatic cancer cell line ( L3. 6pl) at submicromolar dose levels in vitro . In addition, oral treatment with M475271 suppressed the progression of orthotopically implanted L3.6pl cells in a nude mouse model. In the present study, we examined the effect of M475271 on in vitro properties of human lung cancer cell lines expressing various levels of Src protein. We further investigated the therapeutic effect of M475271 on the subcutaneous growth and experimental metastasis produced by human adenocarcinoma cell lines in SCID mice.Materials and methodsSrc expression and activation in NSCLC cell lines as well as M475271 mediated inhibition of phosphorylation of Src and MAPK were assayed with immu-noprecipitation and western blot.MTT assay was used to examine the effect of M475271 on NSCLC cells proliferation.We used collagen I coated transwell chambers to assess the effect of M475271 against cellular invasion in four NSCLC cell lines in vitro .We examined the level of VEGF, activated MMP-2 and MMP-9 in NSCLC cell lines as well as the effect of M475271 on VEGF expression, activated MMP-2 and MMP-9 by ELISA.For the subcutaneous tumor model, A549 cells or PC-9 cells were inoculated into SCID mice by subcutaneous injection. For the lung metastasis model, A549 cells were injected into NK cell-depleted SCID mice via the tail vein.
Mice were orally given every day with or without M475271 to examine the effect of M475271 on the growth of subcutaneous tumor and experimental lung metastasis.Immunohistochemistry was used to show the effect of M475271 on PI and CD31 as well as VEGF expression in subcutaneous tumor and experimental lung metastasis.Results1. Expression of Src and Src phosphorylation in NSCLC cellspp60are was expressed in human bronchial epithelial BEAS2B cell line and all human cancer cell lines used in this study. All five NSCLC cell lines and BEAS2B cell line had autophosphorylated tyrosine-418. The level of phosphorylated Src was highest in PC-9 cells, which was 2-fold higher compared to normal level, followed by A549 cells, 1. 69-fold higher compared to normal level. While nearly no phosphorylated Src in small cell lung cancer SBC5 cell line was detected.2. Effect of M475271 on phosphorylation of SrcM475271 did not affect the level of Src protein expression in all cell lines, however, it reduced the autophosphorylation of Src in a dose-dependent manner in nearly all 5 NSCLC cell lines, especiall in PC-9 and A549 cell lines. 0. 3(xM M475271 nearly inhibited autophosphorylation of Src in PC-9 cells entirely.3. Effect of M475271 on phosphorylation of MAPKM475271 showed a dose-dependent inhibition on phosphorylation of ERK1/ 2. Submicromolar M475271 nearly inhibited phosphorylation of ERK1/2 in PC-9 and A549 entirely. While activated ERK1/2 in other 3 NSCLC cell lines was not sensitive to M475271.4. Effect of M475271 on cell proliferation in vitroThe effect of M475271 on cell proliferation varied significantly among the NSCLC cell lines. PC-9 and A549 cells showed a dose-dependent reduction by M475271. M475271 at 0. 03 ~ 3jjlM suppressed the cell proliferation of PC-9 cells by 11.7% ( P >0.05), 53.6% ( P <0.001), 72.22% ( P <0.001),
82. 39% ( P <0.001) and 90. 56% ( P <0.001) , respectively. Same concentration of M475271 suppressed the cell proliferation of A549 cells by 24.03% ( P <0.05), 30.25% ( P <0.05), 38.54% ( P <0.001), 46.62%( P <0. 001) and 60. 78% ( P <0. 001) , respectively. M475271 at 3julM suppressed the cell proliferation of H226 cells by 20% ( P <0. 001). Same concentration of M475271 had no significant effect on proliferation of PC14PE6 and RERFL-COK ceUs.5. Effect of M475271 on cell invasiveness in vitroInvasiveness of NSCLC cells was suppressed by M475271 in a dose-dependent manner, though there was a little difference in degree of the inhibition among four cell lines. M475271 at 0. 03 ~ ljxM suppressed the cell invasion of PC-9ceUsbyl7.31%( P <0.05), 63.46% ( P <0.001), 82.69% ( P <0. 001) and 91. 69% ( P < 0. 001) , respectively. M475271 at 0. 3 ~ 3u,M suppressed the cell invasion of A549 cells by 36. 35% ( P <0.001) ,77. 9% ( P < 0.001) and 90. 96% ( P < 0. 001) , respectively. M475271 at 1 and 3uJVl could also suppress the cell invasion of PC14PE6 and H226 cells by 54. 73% ( P <0.001) and 79. 1% ( P <0.001) as weU as 36. 88% ( P <0. 001) and 68. 09% ( P < 0. 001 ) , respectively. The MTT assay demonstrated that M475271 did not reduce cells viability at concentrations and times we used for cell invasion assay.6. Effect of M475271 on activated MMP-2 and MMP-9 in NSCLC cells PC14PE6 and H226 cells expressed high MMP-2 and MMP-9 activity,whereas A549 cells expressed only MMP-9 activity. MMP-2 and MMP-9 activity in PC-9 cells was under detection limits. M475271 could obviously inhibited activated MMP-2 in PC14PE6 ceUs and MMP-9 in PC14PE6, H226 and A549 cells in a dose-dependent manner.7. Effect of M475271 on Production of VEGF by NSCLC Cells in vitro We found that M475271 could inhibit the production of VEGF in all threecell lines used in this experiment. In order to verify whether the reduction of VEGF was due to the reduction of cell proliferation, we also performed MTT assay. There was no significant reduction of cells in PC14PE6 and A549 cell lines. In PC-9 cell line, only the concentration of M475271 more than 300nM
could reduce cell proliferation. Standardized the level of VEGF by percentage of cell proliferation indicated that M475271 could significantly inhibit the production of VEGF in a dose-dependent manner, especially in PC-9 and A549 cells.8. Effect of M475271 on subcutaneous Tumor and metastatic lung tumors in SCID miceTreatment with M475271 ( both 10mg/( kg ? d) and 50mg/( kg ? d) ) markedly inhibited the growth of subcutaneous tumors produced by PC-9 cells. After oral feeding with 10mg/( kg ? d) and 50mg/( kg ? d) M475271 for 2 weeks, the volume of subcutaneous tumor was inhibited by 73.28% and 93.4% ( P < 0. 001) , respectively. While the same treatment was less effective to tumors produced by A549 cells, 50mg/( kg ? d) M475271 did not cause significant inhibition until treatment with M475271 3 weeks later, the inhibition rate was about 39.4% ( P <0.05-0.01).A549 cells developed numerous small lesions on the surface of the lung in all groups, but the nodules of the lung in 50mg/( kg ? d) group was smaller than that of control group , representing significantly less lung weight ( P < 0.05). Treatment with 10mg/( kg ? d) M475271 had no significant effect on the lung weight. Treatment with M475271 (both 10 and 50mg/(kg ? d) ) did not cause weight loss of mice significantly, However, inoculated A549 cells 28 days later, the weight in control group was significantly lost( P <0.01).9. Effect of M475271 on cell proliferation and vascularization in vivoIn PC-9 cells induced subcutaneous tumor, 50mg/(kg ? d) M475271 significantly reduced the number of Ki67-positive proliferating tumor cells. The proliferation index (PI) was 22 ±5 and 50 ±8 in treatment and control group, respectively ( P <0.001). In A549 cells induced subcutaneous tumor, 50mg/ (kg ? d) M475271 tended to reduce the number of Ki67-positive proliferating tumor cells. The proliferation index ( PI) was 34 ± Hand 42 ±7 in treatment and control group, respectively ( P >0. 05). Treatment with 50mg/( kg ? d) M475271 not only reduced the number and the size of metastatic lesions, but also inhibited the number of Ki67-positive proliferating tumor cells in lung metas-tases produced by A549 cells ( P <0. 001). PI in control group and treatment group was 59 ± 10 and 24 ±3.
Treatment with 50mg/kg M475271 significantly reduced MVD in both PC-9 ( P < 0.001) and A549( P <0.01)- induced subcutaneous tumors.Moreover, M475271 could greatly reduce the production of VEGF in PC-9 and A549-induced subcutaneous tumors, as well as in lung metastases produced by A549 cells. 50mg/kg M475271 could substantially reduce the phosphorylation of Src at the Y418 site, especially in highly phosphorylated PC-9 induced subcutaneous tumors.DiscussionOver-expression of Src has been detected in a variety of epithelial and non-epithelial malignancy in humans. Mazurenko et al. reported that C-Src protein was found to be elevated in a half of lung cancer patients when determined by immunoblotting and immunohistochemistry, while no pp60 * rc protein was detected in epithelial cells of normal lung tissues. Regarding pp60 "Sre kinase activity, NSCLC, especially adenocarcinoma, had a higher level of pp60CSrc activity compared with colon cancer, which is most often associated with elevated pp60CSrc activity. These findings suggest possible implication of Src in progression of lung adenocarcinoma. Consistently, we found that NSCLC cell lines tested expressed Src protein (pp^SO"0) and have autophosphorylation of tyrosine-418, while there was no over-expression of Src compared with BEAS2B cells, the level of autophosphorylation of tyrosine-418 in NSCLC cells was higher than that in BEAS2B cells, suggesting that phosphorylation ( activation) , but not over-expression, of Src is crucial for tumor-cell invasion and proliferation.Src is a downstream molecule of various growth factor receptors, which regulate cell proliferation and invasion. Src interacts with EGFR that are recognized key molecules for progression of various solid tumors, including lung cancer. Furthermore, since several tumors are known to over-express both EGFR and Src, it is reasonable that they cooperate with each other in signal for cell growth and invasion. Ras/Raf/MEK/MAPK is one of critical cell signal transduction pathways of regulating cell proliferation by Src and EGFR.MAPK has been over activated in many human cancers. Our results showed
that inhibition of Src phosphorylation could suppress the phosphorylation of ERKl/2, which is parallel to the inhibitory effects on cell proliferation in NSCLC cell lines. Therefore, the inhibitory effect of M475271 on NSCLC cells proliferation maybe due to the suppression of ERKl/2, a downstream signal of Src.It is well known that MMPs are crucial for tumor invasion and metastasis. We found that M475271 at high concentration could inhibit MMP-2 and MMP-9 activity. MMP-2 and MMP-9 play a pivotal role in regulating cell mingation and invasion in some NSCLC cells, but other factors was also involved in regulating NSCLC cells invasion.Recent reports indicate that Src is one of critical molecules regulating an-giogenesis. Activation of Src stimulates VEGF protein production from various types of cell lines, and Src cooperates with VEGF receptors ( KDR/Flk-1) in endothelial cells, and hence stimulates endothelial proliferation. In fact, Ellis et al reported that transfection of antisense C-Src down-regulated VEGF production of colon cancer cells and inhibited tumor vascularization. In the present study, daily oral administration of M475271 suppressed the growth of subcutaneous tumors produced by PC-9 and A549 cells, accompanied with the inhibition of vascularization as well as tumor cell proliferation in vivo . VEGF production in the tumors was also inhibited by treatment with M475271, angiogenesis inhibition by this compound may be mediated by, at least in part, inhibition of the production of VEGF. Therefore, angiogenesis inhibition is regarded as one of the possible mechanisms of antitumor effects by M475271.The process of metastasis involves several sequentially linked steps. We e-quated experimental lung metastasis with the blood-borne spread of A549 cells. Although tumor cells had bypassed the initial steps of metastasis ( separation from the primary neoplasm, invasion, and release into blood vessels and lymphatics ) , all subsequent steps in the process for formation of metastases (arrest at a distant site, extravasation, invasion and proliferation with angiogenesis in the lung) must have occurred. M475271 treatment started 7 days after tumor-cell injection (after the establishment of micrometastasis) inhibited the production of experimental lung metastasis of A549 cells, representing reduced lung
近年来非小细胞肺癌药物治疗的新策略转向抑制肿瘤生长进展中特异性通路和关键分子的分子靶向治疗。其中,表皮生长因子受体(EGFR)酪氨酸激酶抑制剂已成功地用于治疗某些晚期非小细胞肺癌。相对于鳞癌,EGFR酪氨酸激酶抑制剂对于腺癌更有效,然而也只是部分腺癌患者有临床反应。因此,有必要加强对其它重要的靶分子的研究。
Src是最早报道的癌基因,作为原型与后来发现的其它癌基因有着共同的特点。反转录病毒基因V-Src具有致癌性,其同源的原癌基因C-Src是人或动物细胞中的正常基因,它们编码分子量为60kD的非受体蛋白酪氨酸激酶。Src蛋白在调控细胞的生长(生存和增生)、黏附、运动和细胞信号转导等方面发挥重要作用。人类很多肿瘤,例如结肠癌、乳腺癌和胰腺癌,都存在Src蛋白的过度表达和/或活化,Src在肿瘤的发生、发展和转移中具有重要作用。近年来有人发现,与正常肺组织相比,半数肺癌中C-Src蛋白的表达增高,小细胞肺癌C-Src激酶活性较低,非小细胞肺癌,特别是腺癌中,C-Src激酶活性明显增高。随着腺癌肿块的增大,C-Src激酶活性也增高,与腺癌的进展相关。低分化鳞癌中C-Src蛋白的表达明显高于中高分化的鳞癌。C-Src蛋白在非小细胞肺癌中的高表达和高活化,提示Src可以
IntroductionNon-small cell lung cancer ( NSCLC) accounts for about 80% of all lung cancers. Although some progress has been made in the treatment of NSCLC, NSCLC remains the leading cause of cancer-related mortality in most countries. The majority of the diagnosed patients with NSCLC are in advanced stage because of its highly metastatic properties, and such patients are not candidates for surgical resection. Although systemic chemotherapy reduces the rate of death attributable to advanced NSCLC, disease progression is inevitable and dose-limiting toxicities restrict its use.A novel strategy for chemorefractory NSCLC in advanced stage is molecular-ly targeted therapy inhibiting specific pathways and key molecules implicated in tumor growth and progression. Among molecularly targeted therapies, inhibitors of epidermal growth factor receptor (EGFR) -tyrosine kinases have been successfully developed for advanced NSCLC. Although EGFR inhibitors are more effective for adenocarcinoma compared with squamous cell carcinoma, the clinical responses are observed only in some populations of the patients even in adenocarcinoma. Therefore, novel drugs targeting other critical molecules are required for patients with NSCLC.Src is the first reported oncogene and has been a prototype in identifying many characteristics of follow on oncogenes. C-Src and its retroviral form ( V-Src) are both non-receptor tyrosine kinases, encoding a Mr 60,000 membrane -associated protein tyrosine kinase ( PTK). Results from many different studies suggest a role of Src in various aspects of a cell's life, including proliferation,
survival, motility, cell-cell and cell - matrix adhesion, and local invasion, all of which are deregulated during cancer progression. C-Src has been found to be over-expressed and highly activated in a variety of human cancers, including colon cancer, breast cancer, and pancreatic cancer. Recent studies showed that the proto-oncogene C-Src was also highly activated in NSCLC, especially in ade-nocarcinomas, suggesting the possibility of molecular targeted therapy for lung adenocarcinoma.M475271 is a novel, orally available selective inhibitor of Src kinases. It has potential to inhibit migration of the highly metastatic human pancreatic cancer cell line ( L3. 6pl) at submicromolar dose levels in vitro . In addition, oral treatment with M475271 suppressed the progression of orthotopically implanted L3.6pl cells in a nude mouse model. In the present study, we examined the effect of M475271 on in vitro properties of human lung cancer cell lines expressing various levels of Src protein. We further investigated the therapeutic effect of M475271 on the subcutaneous growth and experimental metastasis produced by human adenocarcinoma cell lines in SCID mice.Materials and methodsSrc expression and activation in NSCLC cell lines as well as M475271 mediated inhibition of phosphorylation of Src and MAPK were assayed with immu-noprecipitation and western blot.MTT assay was used to examine the effect of M475271 on NSCLC cells proliferation.We used collagen I coated transwell chambers to assess the effect of M475271 against cellular invasion in four NSCLC cell lines in vitro .We examined the level of VEGF, activated MMP-2 and MMP-9 in NSCLC cell lines as well as the effect of M475271 on VEGF expression, activated MMP-2 and MMP-9 by ELISA.For the subcutaneous tumor model, A549 cells or PC-9 cells were inoculated into SCID mice by subcutaneous injection. For the lung metastasis model, A549 cells were injected into NK cell-depleted SCID mice via the tail vein.
Mice were orally given every day with or without M475271 to examine the effect of M475271 on the growth of subcutaneous tumor and experimental lung metastasis.Immunohistochemistry was used to show the effect of M475271 on PI and CD31 as well as VEGF expression in subcutaneous tumor and experimental lung metastasis.Results1. Expression of Src and Src phosphorylation in NSCLC cellspp60are was expressed in human bronchial epithelial BEAS2B cell line and all human cancer cell lines used in this study. All five NSCLC cell lines and BEAS2B cell line had autophosphorylated tyrosine-418. The level of phosphorylated Src was highest in PC-9 cells, which was 2-fold higher compared to normal level, followed by A549 cells, 1. 69-fold higher compared to normal level. While nearly no phosphorylated Src in small cell lung cancer SBC5 cell line was detected.2. Effect of M475271 on phosphorylation of SrcM475271 did not affect the level of Src protein expression in all cell lines, however, it reduced the autophosphorylation of Src in a dose-dependent manner in nearly all 5 NSCLC cell lines, especiall in PC-9 and A549 cell lines. 0. 3(xM M475271 nearly inhibited autophosphorylation of Src in PC-9 cells entirely.3. Effect of M475271 on phosphorylation of MAPKM475271 showed a dose-dependent inhibition on phosphorylation of ERK1/ 2. Submicromolar M475271 nearly inhibited phosphorylation of ERK1/2 in PC-9 and A549 entirely. While activated ERK1/2 in other 3 NSCLC cell lines was not sensitive to M475271.4. Effect of M475271 on cell proliferation in vitroThe effect of M475271 on cell proliferation varied significantly among the NSCLC cell lines. PC-9 and A549 cells showed a dose-dependent reduction by M475271. M475271 at 0. 03 ~ 3jjlM suppressed the cell proliferation of PC-9 cells by 11.7% ( P >0.05), 53.6% ( P <0.001), 72.22% ( P <0.001),
82. 39% ( P <0.001) and 90. 56% ( P <0.001) , respectively. Same concentration of M475271 suppressed the cell proliferation of A549 cells by 24.03% ( P <0.05), 30.25% ( P <0.05), 38.54% ( P <0.001), 46.62%( P <0. 001) and 60. 78% ( P <0. 001) , respectively. M475271 at 3julM suppressed the cell proliferation of H226 cells by 20% ( P <0. 001). Same concentration of M475271 had no significant effect on proliferation of PC14PE6 and RERFL-COK ceUs.5. Effect of M475271 on cell invasiveness in vitroInvasiveness of NSCLC cells was suppressed by M475271 in a dose-dependent manner, though there was a little difference in degree of the inhibition among four cell lines. M475271 at 0. 03 ~ ljxM suppressed the cell invasion of PC-9ceUsbyl7.31%( P <0.05), 63.46% ( P <0.001), 82.69% ( P <0. 001) and 91. 69% ( P < 0. 001) , respectively. M475271 at 0. 3 ~ 3u,M suppressed the cell invasion of A549 cells by 36. 35% ( P <0.001) ,77. 9% ( P < 0.001) and 90. 96% ( P < 0. 001) , respectively. M475271 at 1 and 3uJVl could also suppress the cell invasion of PC14PE6 and H226 cells by 54. 73% ( P <0.001) and 79. 1% ( P <0.001) as weU as 36. 88% ( P <0. 001) and 68. 09% ( P < 0. 001 ) , respectively. The MTT assay demonstrated that M475271 did not reduce cells viability at concentrations and times we used for cell invasion assay.6. Effect of M475271 on activated MMP-2 and MMP-9 in NSCLC cells PC14PE6 and H226 cells expressed high MMP-2 and MMP-9 activity,whereas A549 cells expressed only MMP-9 activity. MMP-2 and MMP-9 activity in PC-9 cells was under detection limits. M475271 could obviously inhibited activated MMP-2 in PC14PE6 ceUs and MMP-9 in PC14PE6, H226 and A549 cells in a dose-dependent manner.7. Effect of M475271 on Production of VEGF by NSCLC Cells in vitro We found that M475271 could inhibit the production of VEGF in all threecell lines used in this experiment. In order to verify whether the reduction of VEGF was due to the reduction of cell proliferation, we also performed MTT assay. There was no significant reduction of cells in PC14PE6 and A549 cell lines. In PC-9 cell line, only the concentration of M475271 more than 300nM
could reduce cell proliferation. Standardized the level of VEGF by percentage of cell proliferation indicated that M475271 could significantly inhibit the production of VEGF in a dose-dependent manner, especially in PC-9 and A549 cells.8. Effect of M475271 on subcutaneous Tumor and metastatic lung tumors in SCID miceTreatment with M475271 ( both 10mg/( kg ? d) and 50mg/( kg ? d) ) markedly inhibited the growth of subcutaneous tumors produced by PC-9 cells. After oral feeding with 10mg/( kg ? d) and 50mg/( kg ? d) M475271 for 2 weeks, the volume of subcutaneous tumor was inhibited by 73.28% and 93.4% ( P < 0. 001) , respectively. While the same treatment was less effective to tumors produced by A549 cells, 50mg/( kg ? d) M475271 did not cause significant inhibition until treatment with M475271 3 weeks later, the inhibition rate was about 39.4% ( P <0.05-0.01).A549 cells developed numerous small lesions on the surface of the lung in all groups, but the nodules of the lung in 50mg/( kg ? d) group was smaller than that of control group , representing significantly less lung weight ( P < 0.05). Treatment with 10mg/( kg ? d) M475271 had no significant effect on the lung weight. Treatment with M475271 (both 10 and 50mg/(kg ? d) ) did not cause weight loss of mice significantly, However, inoculated A549 cells 28 days later, the weight in control group was significantly lost( P <0.01).9. Effect of M475271 on cell proliferation and vascularization in vivoIn PC-9 cells induced subcutaneous tumor, 50mg/(kg ? d) M475271 significantly reduced the number of Ki67-positive proliferating tumor cells. The proliferation index (PI) was 22 ±5 and 50 ±8 in treatment and control group, respectively ( P <0.001). In A549 cells induced subcutaneous tumor, 50mg/ (kg ? d) M475271 tended to reduce the number of Ki67-positive proliferating tumor cells. The proliferation index ( PI) was 34 ± Hand 42 ±7 in treatment and control group, respectively ( P >0. 05). Treatment with 50mg/( kg ? d) M475271 not only reduced the number and the size of metastatic lesions, but also inhibited the number of Ki67-positive proliferating tumor cells in lung metas-tases produced by A549 cells ( P <0. 001). PI in control group and treatment group was 59 ± 10 and 24 ±3.
Treatment with 50mg/kg M475271 significantly reduced MVD in both PC-9 ( P < 0.001) and A549( P <0.01)- induced subcutaneous tumors.Moreover, M475271 could greatly reduce the production of VEGF in PC-9 and A549-induced subcutaneous tumors, as well as in lung metastases produced by A549 cells. 50mg/kg M475271 could substantially reduce the phosphorylation of Src at the Y418 site, especially in highly phosphorylated PC-9 induced subcutaneous tumors.DiscussionOver-expression of Src has been detected in a variety of epithelial and non-epithelial malignancy in humans. Mazurenko et al. reported that C-Src protein was found to be elevated in a half of lung cancer patients when determined by immunoblotting and immunohistochemistry, while no pp60 * rc protein was detected in epithelial cells of normal lung tissues. Regarding pp60 "Sre kinase activity, NSCLC, especially adenocarcinoma, had a higher level of pp60CSrc activity compared with colon cancer, which is most often associated with elevated pp60CSrc activity. These findings suggest possible implication of Src in progression of lung adenocarcinoma. Consistently, we found that NSCLC cell lines tested expressed Src protein (pp^SO"0) and have autophosphorylation of tyrosine-418, while there was no over-expression of Src compared with BEAS2B cells, the level of autophosphorylation of tyrosine-418 in NSCLC cells was higher than that in BEAS2B cells, suggesting that phosphorylation ( activation) , but not over-expression, of Src is crucial for tumor-cell invasion and proliferation.Src is a downstream molecule of various growth factor receptors, which regulate cell proliferation and invasion. Src interacts with EGFR that are recognized key molecules for progression of various solid tumors, including lung cancer. Furthermore, since several tumors are known to over-express both EGFR and Src, it is reasonable that they cooperate with each other in signal for cell growth and invasion. Ras/Raf/MEK/MAPK is one of critical cell signal transduction pathways of regulating cell proliferation by Src and EGFR.MAPK has been over activated in many human cancers. Our results showed
that inhibition of Src phosphorylation could suppress the phosphorylation of ERKl/2, which is parallel to the inhibitory effects on cell proliferation in NSCLC cell lines. Therefore, the inhibitory effect of M475271 on NSCLC cells proliferation maybe due to the suppression of ERKl/2, a downstream signal of Src.It is well known that MMPs are crucial for tumor invasion and metastasis. We found that M475271 at high concentration could inhibit MMP-2 and MMP-9 activity. MMP-2 and MMP-9 play a pivotal role in regulating cell mingation and invasion in some NSCLC cells, but other factors was also involved in regulating NSCLC cells invasion.Recent reports indicate that Src is one of critical molecules regulating an-giogenesis. Activation of Src stimulates VEGF protein production from various types of cell lines, and Src cooperates with VEGF receptors ( KDR/Flk-1) in endothelial cells, and hence stimulates endothelial proliferation. In fact, Ellis et al reported that transfection of antisense C-Src down-regulated VEGF production of colon cancer cells and inhibited tumor vascularization. In the present study, daily oral administration of M475271 suppressed the growth of subcutaneous tumors produced by PC-9 and A549 cells, accompanied with the inhibition of vascularization as well as tumor cell proliferation in vivo . VEGF production in the tumors was also inhibited by treatment with M475271, angiogenesis inhibition by this compound may be mediated by, at least in part, inhibition of the production of VEGF. Therefore, angiogenesis inhibition is regarded as one of the possible mechanisms of antitumor effects by M475271.The process of metastasis involves several sequentially linked steps. We e-quated experimental lung metastasis with the blood-borne spread of A549 cells. Although tumor cells had bypassed the initial steps of metastasis ( separation from the primary neoplasm, invasion, and release into blood vessels and lymphatics ) , all subsequent steps in the process for formation of metastases (arrest at a distant site, extravasation, invasion and proliferation with angiogenesis in the lung) must have occurred. M475271 treatment started 7 days after tumor-cell injection (after the establishment of micrometastasis) inhibited the production of experimental lung metastasis of A549 cells, representing reduced lung
引文
1. Travis WD, Colby TV, Corrin B. World Health Organization classification of Lung and pleural tumors. 3rd ed. Berlin: Springer - Verlag; 1999.
2. Devita VT, Hellman S, Rosenberg SA. Cancer Principles & Practice of On-cology. 6th ed. 2001. Philadelphia; Lippincott Williams & Wilkins, 2001,925-75.
3. William LR. The epidemiology of bronchioloalveolar carcinoma. ASCO An-nual Meeting, Session; Lung Cancer, 2002.
4. Manegold C. Chemotherapy for advanced non - small cell lung cancer; standards. Lung Cancer 2001; 34 Suppl 2; S165 -70.
5. Broker LE, Giaccone G. The role of new agents in the treatment of non -small cell lung cancer. Eur J Cancer 2002; 38(18): 2347 -61.
6. Sandier AB. Molecular targeted agents in non - small - cell lung cancer.Clin Lung Cancer 2003; 5 Suppl 1 :S22 -8.
7. Gelibter A, Ceribelli A, Milella M, Mottolese M, Vocaturo A, Cognetti F. Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib (lressa, ZD1839) in non small cell lung cancer. J Exp Clin Cancer Res 2003; 22(3): 481-5.
8. Ohe Y, Saijo N. Results of recent Japanese clinical trials in lung cancer. Clin Lung Cancer 2002; 3 (4 ): 243 - 8.
9. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non - small - cell lung cancer. J Clin Oncol 2004; 22(6) : 1103-9.
10. Stehelin D, Varmus HE, Bishop JM, and Vogt PK. DNA related to the transforming gene (s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976; (260): 170-3.
11. Martin GS. The hunting of the Src. Nat Mol Cell Biol 2001; (2) : 467 -75.
12. Jove R, Hanafusa H. Cell transformation by the viral src oncogene. Annu. Rev. Cell Biol 1987; (3) : 31 -56.
13. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases.
Annu Rev Cell Dev Biol 1997; (13): 513 -609.
14. Frame MC. Src in cancer; deregulation and consequences for cell behav-iour. Biochim Biophys Acta 2002; (1602) : 114 -30.
15. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kina-ses: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003; 9(25) : 2043 -59.
16. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996; 1287(2 -3) : 121 -49.
17. Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp CeU Res 2000 Jan 10;254( 1):1 -13.
18. Riley D, Carragher NO, Frame MC, Wyke JA. The mechanism of cell cycle regulation by v -Src. Oncogene 2001 Sep 20; 20(42) :5941 -50.
19. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R. Stat3 - mediated Myc expression is required for Src transformation and PDGF - induced mitogene-sis. Proc Natl Acad Sci USA 2001 Jun 19;98( 13):7319 -24. Epub 2001 Jun 12.
20. Johnson D, Agochiya M, Samejima K, Earnshaw W, Frame M, Wyke J. Regulation of both apoptosis and cell survival by the v - Src oncoprotein. CeU Death Differ 2000 Aug;7(8):685 -96.
21. Khwaja A, Rodriguez - Viciana P, Wennstrom S, Warne PH, Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3 -OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997 May 15;16(10) :2783 -93.
22. Irby RB, Yeatman TJ. Role of Src expression and activation in human canc-er. Oncogene 2000; 19(49): 5636-42.
23. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W. pp60c - src activation in human colon carcinoma. J Clin Invest 1989 Jun;83(6) :2025-33.
24. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c - src in progressive stages of human colorectal cancer. J Clin Invest 1993 Jan;91(l) :53 -60.
25. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002 Jan 15;94(2) :344 -51.
26. Ottenhoff - Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c - src oncogene product. Cancer Res 1992 Sepl;52(17):4773-8.
27. Verbeek BS, Vroom TM, Adriaansen - Slot SS, Ottenhoff - Kalff AE, Geertzema JG, Hennipman A, Rijksen G. c -Src protein expression is in-creased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996 Dec; 180(4) :383 -8.
28. Budde RJ, Ke S, Levin VA. Activity of pp60c - src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 1994; 14(3) : 171 -5.
29. Masaki T, Igarashi K, Tokuda M, et al. pp60c —src activation in lung ade-nocarcinoma. Eur J Cancer 2003; 39(10) : 1447 -55.
30. Mazurenko NN, Kogan EA, Zborovskaya IB and Kisseliov FL. Expression of pp60c - src in human small cell and non - small cell lung carcinoma. Eur J Cancer 1992; 28 (2 -3) : 372 -7.
31. Yezhelyev M, Wagner C, Kohl G, et al. In vivo and In vitro effects of a no-vel src kinase inhibitor on human pancreatic cancer in a nude mouse model. Proc AACO 2003 April 5-9.
32. Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA. Analy-sis of pp60c - src protein kinase activity in human tumor cell lines and tis-sues. J Biol Chem 1986 Oct 15;261(29):13754 -9.
33. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer in-vasion. Physiol Rev 2003; 83: 337 -76.
34. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs.TIBS 1995; 20:117 -22.
35.Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J. The cell proliferation - associated antigen of antibody Ki - 67: a very large, ubiquitous nuclear protein with numerous repeated elements, re- presenting a new kind of cell cycle - maintaining proteins. J Cell Biol 1993 Nov;123(3):513-22.
36. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stah-mer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular bi-ologic characterization of the cell proliferation - associated nuclear antigen that is defined by monoclonal antibody Ki -67. Am J Pathol 1991 Apr; 138(4):867-73.
37. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell prolifera-tion. Int J Cancer 1983 Jan 15 ;31 (1) : 13 -20.
38. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associat-ed antigen on routinely processed tissue sections. J Clin Pathol 1990 Sep;43 (9):752-7.
39. Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lympho-kines. J Immunol Methods 1984; 70: 257 -68.
40. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;(324): 1-8.
41. Ferrandina G, Ranelletti FO, Larocca LM, et al. Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancer. Clin Cancer Res 2001; 7(9) : 2656 -61.
42. Simeonova PP, Wang S, Hulderman T, Luster MI. c -Src -dependent ac-tivation of the epidermal growth factor receptor and mitogen - activated pro-tein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem 2002 Jan 25; 277(4): 2945 -50. Epub 2001 Nov 26.
43. Lotz M, Wang HH, Cance W, Matthews J, Pories S. Epidermal growth fac-tor stimulation can substitute for c - Src overexpression in promoting breast carcinoma invasion. J Surg Res 2003; 109(2) : 123-9.
44. Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c - Src interactions in human breast tumor cells.
Mol Carcinog 1998; 21(4) : 261 -72.
45. Stover DR, Becker M, Liebetanz J, Lydon NB. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem 1995; 270(26): 15591 -7.
46. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000 ;77 : 25 -79.
47. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient ver-sus sustained extracellular signal - regulated kinase activation. Cell 1995 Jan 27;80(2):179-85.
48. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 139 -49.
49. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi - Galluzi C, Stork PJS. Expression of mitogen - activated protein ki-nase phosphatase - 1 in the early phases of human epithelial carcinogenesis. Am J Pathol, 1996; 149: 1553 -64.
50. Magi -Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodie-ci P, Wishnow K, Kaplan I, Stork PJ, Loda M. Mitogen -activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely re-lated to apoptosis. Lab Investig 1997; 76: 37 -51.
51. Oka H, Chatani Y, Boshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y,Kawaichi M, Kohno M, Yoshida 0. Constitutive activation of mitogen -ac-tivated protein ( MAP) kinases in human renal cell carcinoma Cancer Res 1995 ;55: 4182-87.
52. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T,Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N, Hori M. Ac-tivation of mitogen - activated protein kinases/extracellular signal - regula-ted kinases in human hepatocellular carcinoma. Hepatology 1998 ;27:951 -8.
53. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida 0. Shimada Y, Ari - i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41 -/43 - kDa mitogen - activated protein kinase signaling pathway in hu-
man tumors. Oncogene 1999; 18: 813 -22.
54. Gioeli D, Mandell JW, Petroni GR, Frierson HFJ, Weber MJ. Activation of mitogen - activated protein kinase associated with prostate cancer progres-sion. Cancer Res 1999;59: 279 -84.
55. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling: immunohistochemical lo-calization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998;153: 1411-23.
56. Gee J, Barroso A, Ellis I, Robertson J, Nicholson R. Biological and clini-cal associations of c - jun activation in human breast cancer. Int J Cancer 2000 ;89: 177-86.
57. Staley CA, Parikh NU, Gallick GE. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c - Src. CeU Growth Differ 1997 ;8(3) : 269 -74.
58. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and me-tastasis. J Pathol 1999 Nov; 189(3) :300 -8.
59. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000 Jan 20;57(1):5 - 15.
60. O'Connor CM, FitzGerald MX. Matrix metalloproteases and lung disease.Thorax 1994 Jun;49(6):602 -9.
61. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metallo-proteinases: biologic activity and clinical implications. J Clin Oncol 2000 Mar;18(5):1135-49.
62. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D,Kemp B, Lee JJ, Hong WK, Fidler U. Differential expression of E - cad-herin and type IV collagenase genes predicts outcome in patients with stage I non - small cell lung carcinoma. Clin Cancer Res 2000 Mar;6(3):790 -7.
63. Talbot DC, Brown PD. Experimental and clinical studies on the use of ma-trix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996 Dec;32A(14):2528-33.
64. Martinella - Catusse C, Nawrocki B, Gilles C, Birembaut P, Polette M. Matrix - metalloproteinases in bronchopulmonary carcinomas. Histol His-
topathol 1999 Jul;14(3) :839-43.
65. Ito H, Gardner - Thorpe J, Zinner MJ, Ashley SW, Whang EE. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003; 134:221-6.
66. Recchia I, Rucci N, Festuccia C, Bologna M, MacKay AR, Migliaccio S,Longo M, Susa M, Fabbro D, Teti A. Pyrrolopyrimidine c - Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003; 39:1927 - 35.
67. Verheijen JH, Nieuwenbroek NM, Beekman B, Hanemaaijer R, Verspaget HW, Ronday HK, Bakker AH. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and ma-trix metalloproteinase activity using modified pro - urokinase. Biochem J 1997 May 1 ;323 ( Pt 3) :603 -9.
68. Shiraga M, Yano S, Yamamoto A, Ogawa H, Goto H, Miki T, Miki K, Zhang H, Sone S. Organ heterogeneity of host - derived matrix metallopro-teinase expression and its involvement in multiple - organ metastasis by lung cancer cell lines. Cancer Res 2002 Oct 15;62(20) :5967 -73.
69. Albini A, Iwamoto Y, Kleinman H K, et al. A rapid in vitro assay for quan-titating the invasive potential of tumor cells. Cancer Res 1987; 47 ( 12) :3239-45.
70. Yano S, Nishioka Y, Izumi K, Tsuruo T, Tanaka T, Miyasaka M, Sone S.Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996; 67(2): 211 -7.
71. Liotta LA. Tumor invasion and metastases - - role of the extracellular ma-trix: Rhoads Memorial Award lecture. Cancer Res 1986 Jan;46(l) :1 -7.
72. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling.Trends Genet. 1990 Apr;6(4):121 -5.
73. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DR. Dis-tribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991 Nov 11 ;49(5) :666 -72.
74. Ylisirnio S, Hoyhtya M, Turpeenniemi - Hujanen T. Serum matrix metallo-proteinases - 2, - 9 and tissue inhibitors of metalloproteinases -1, - 2 in
lung cancer----TIMP -1 as a prognostic marker. Anticancer Res 2000Mar-Apr;20(2B):.1311-6.
75. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. Ex-pression of matrix metalloproteinase ( gelatinase) in Tl adenocarcinoma of the lung. Pathol Int 1997 Jul;47(7) :461 -9.
76. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72 - kilodalton gelatinase and tumor spread in non - small - cell lung carcinoma. J Natl Cancer Inst 1993 Apr 7; 85(7):574-8.
77. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expres-sion in tumor invasion. FASEB J 1999 May; 13(8) :781 -92.
78. Sato H, Kita M, Seiki M. v - Src activates the expression of 92 - kDa type IV collagenase gene through the AP -1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression in-dependent of that by inflammatory cytokines. J Biol Chem 1993 Nov 5; 268(31):23460-8.
79. Brunton VG, Ozanne BW, Paraskeva C, et al. A role for epidermal growth factor receptor, c - Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene 1997; 14(3) :283 -93.
80. Sone S, Shinohara T, Nishioka Y, Yano S. Symposium on molecular patho-genesis of respiratory diseases and its clinical implication. Molecular patho-genesis of lung cancer and its molecular targeted therapy. Intern Med 2001;40(2); 167-70.
81. Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogene-sis in non - small cell lung cancer, and therapeutics targeting related mole-cules. Cancer Sci 2003 Jun;94(6):479 -85.
82. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non - small - cell lung carcinoma: a pro-spective study. J Natl Cancer Inst 1997; 89: 881 -6.
83. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yama-da T, Hanaoka N, Inui K, Wada H. Evaluation of angiogenesis in non -
small cell lung cancer: comparison between anti - CD34 antibody and anti -CD105 antibody. Clin Cancer Res 2001; 7: 3410 -5.
84. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, Sculier JP. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta - analysis. Br J Cancer 2002; 87: 694 -701.
85. Folkman J, DAmore PA. Blood vessel formation: what is its molecular ba-sis? CeU 1996 Dec 27 ;87(7):1153-5.
86. Scappaticci FA. Mechanisms and future directions for angiogenesis - based cancer therapies. J Clin Oncol 2002; 20: 3906 -27.
87. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor;a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368 -80.
88. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. Vascular endothelial growth factor is asso-ciated with neovascularization and influences progression of non - small cell lung carcinoma. Clin Cancer Res 1997; 3: 861 -5.
89. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Vascu-lar endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 1999; 48: 396 -400.
90. Fleming RY, Ellis LM, Parikh NU, Iiu W, Staley CA, Gallick GE. Regu-lation of vascular endothelial growth factor expression in human colon carci-noma cells by activity of src kinase. Surgery 1997 Aug;122(2) :501 -7.
91. Munshi N, Groopman JE, Gill PS, Ganju RK. c -Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells. J Immunol 2000 Feb 1;164(3) :1169-74.
92. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998 Sep 18;94(6) :715 -25.
93. Cox G, Jones JL, Walker RA, Steward WP, OByrne KJ. Angiogenesis and non - small cell lung cancer. Lung Cancer 2000 Feb;27(2) :81 -100.
94. Mitzner W, Lee W, Georgakopoulos D, Wagner E. Angiogenesis in the mouse lung. Am J Pathol 2000 Jul; 157 (1):93 -101.
95.Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K. Broad antitumor and antiangiogenic activities of AG3340, a potent and se-lective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999 Jun 30;878:236 -70.
96. Aikawa H, Takahashi H, Fujimura S, Sato M, Endo C, Sakurada A, Kon-do T, Tanita T, Matsumura Y, Ono S, Saito Y, Sagawa M. Immunohisto- chemical study on tumor angiogenic factors in non - small cell lung cancer. Anticancer Res 1999 Sep -Oct;19(5B) :4305 -9.
97. Shibuya M. Structure and function of VEGF/VEGF - receptor system in-volved in angiogenesis. Cell Struct Funct 2001 Feb;26(l) :25 -35.
98. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-68.
99. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S and Tominaga T. Vascu-lar endothelial growth factor and platelet - derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast canc-er. Clin Cancer Res 1995 ;1: 961 -4.
100. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell pro-liferation in human epidermoid lung carcinoma. Br J Cancer 1996 Apr; 73 (7):931-4.
101. Boldrini L, Calcinai A, Silvestri V, Basolo F, Lucchi M, Mussi A, Ange-letti CA, Bevilacqua G, Fontanini G. Quantitation by competitive PCR as-say of vascular endothelial growth factor in non - small cell lung carcino-mas. Int J Oncol 1999 Jan;14(1) :161 -8.
102. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into
2. Devita VT, Hellman S, Rosenberg SA. Cancer Principles & Practice of On-cology. 6th ed. 2001. Philadelphia; Lippincott Williams & Wilkins, 2001,925-75.
3. William LR. The epidemiology of bronchioloalveolar carcinoma. ASCO An-nual Meeting, Session; Lung Cancer, 2002.
4. Manegold C. Chemotherapy for advanced non - small cell lung cancer; standards. Lung Cancer 2001; 34 Suppl 2; S165 -70.
5. Broker LE, Giaccone G. The role of new agents in the treatment of non -small cell lung cancer. Eur J Cancer 2002; 38(18): 2347 -61.
6. Sandier AB. Molecular targeted agents in non - small - cell lung cancer.Clin Lung Cancer 2003; 5 Suppl 1 :S22 -8.
7. Gelibter A, Ceribelli A, Milella M, Mottolese M, Vocaturo A, Cognetti F. Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib (lressa, ZD1839) in non small cell lung cancer. J Exp Clin Cancer Res 2003; 22(3): 481-5.
8. Ohe Y, Saijo N. Results of recent Japanese clinical trials in lung cancer. Clin Lung Cancer 2002; 3 (4 ): 243 - 8.
9. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non - small - cell lung cancer. J Clin Oncol 2004; 22(6) : 1103-9.
10. Stehelin D, Varmus HE, Bishop JM, and Vogt PK. DNA related to the transforming gene (s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976; (260): 170-3.
11. Martin GS. The hunting of the Src. Nat Mol Cell Biol 2001; (2) : 467 -75.
12. Jove R, Hanafusa H. Cell transformation by the viral src oncogene. Annu. Rev. Cell Biol 1987; (3) : 31 -56.
13. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases.
Annu Rev Cell Dev Biol 1997; (13): 513 -609.
14. Frame MC. Src in cancer; deregulation and consequences for cell behav-iour. Biochim Biophys Acta 2002; (1602) : 114 -30.
15. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kina-ses: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003; 9(25) : 2043 -59.
16. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996; 1287(2 -3) : 121 -49.
17. Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp CeU Res 2000 Jan 10;254( 1):1 -13.
18. Riley D, Carragher NO, Frame MC, Wyke JA. The mechanism of cell cycle regulation by v -Src. Oncogene 2001 Sep 20; 20(42) :5941 -50.
19. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R. Stat3 - mediated Myc expression is required for Src transformation and PDGF - induced mitogene-sis. Proc Natl Acad Sci USA 2001 Jun 19;98( 13):7319 -24. Epub 2001 Jun 12.
20. Johnson D, Agochiya M, Samejima K, Earnshaw W, Frame M, Wyke J. Regulation of both apoptosis and cell survival by the v - Src oncoprotein. CeU Death Differ 2000 Aug;7(8):685 -96.
21. Khwaja A, Rodriguez - Viciana P, Wennstrom S, Warne PH, Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3 -OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997 May 15;16(10) :2783 -93.
22. Irby RB, Yeatman TJ. Role of Src expression and activation in human canc-er. Oncogene 2000; 19(49): 5636-42.
23. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W. pp60c - src activation in human colon carcinoma. J Clin Invest 1989 Jun;83(6) :2025-33.
24. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c - src in progressive stages of human colorectal cancer. J Clin Invest 1993 Jan;91(l) :53 -60.
25. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002 Jan 15;94(2) :344 -51.
26. Ottenhoff - Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c - src oncogene product. Cancer Res 1992 Sepl;52(17):4773-8.
27. Verbeek BS, Vroom TM, Adriaansen - Slot SS, Ottenhoff - Kalff AE, Geertzema JG, Hennipman A, Rijksen G. c -Src protein expression is in-creased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996 Dec; 180(4) :383 -8.
28. Budde RJ, Ke S, Levin VA. Activity of pp60c - src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 1994; 14(3) : 171 -5.
29. Masaki T, Igarashi K, Tokuda M, et al. pp60c —src activation in lung ade-nocarcinoma. Eur J Cancer 2003; 39(10) : 1447 -55.
30. Mazurenko NN, Kogan EA, Zborovskaya IB and Kisseliov FL. Expression of pp60c - src in human small cell and non - small cell lung carcinoma. Eur J Cancer 1992; 28 (2 -3) : 372 -7.
31. Yezhelyev M, Wagner C, Kohl G, et al. In vivo and In vitro effects of a no-vel src kinase inhibitor on human pancreatic cancer in a nude mouse model. Proc AACO 2003 April 5-9.
32. Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA. Analy-sis of pp60c - src protein kinase activity in human tumor cell lines and tis-sues. J Biol Chem 1986 Oct 15;261(29):13754 -9.
33. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer in-vasion. Physiol Rev 2003; 83: 337 -76.
34. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs.TIBS 1995; 20:117 -22.
35.Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J. The cell proliferation - associated antigen of antibody Ki - 67: a very large, ubiquitous nuclear protein with numerous repeated elements, re- presenting a new kind of cell cycle - maintaining proteins. J Cell Biol 1993 Nov;123(3):513-22.
36. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stah-mer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular bi-ologic characterization of the cell proliferation - associated nuclear antigen that is defined by monoclonal antibody Ki -67. Am J Pathol 1991 Apr; 138(4):867-73.
37. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell prolifera-tion. Int J Cancer 1983 Jan 15 ;31 (1) : 13 -20.
38. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associat-ed antigen on routinely processed tissue sections. J Clin Pathol 1990 Sep;43 (9):752-7.
39. Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lympho-kines. J Immunol Methods 1984; 70: 257 -68.
40. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;(324): 1-8.
41. Ferrandina G, Ranelletti FO, Larocca LM, et al. Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancer. Clin Cancer Res 2001; 7(9) : 2656 -61.
42. Simeonova PP, Wang S, Hulderman T, Luster MI. c -Src -dependent ac-tivation of the epidermal growth factor receptor and mitogen - activated pro-tein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem 2002 Jan 25; 277(4): 2945 -50. Epub 2001 Nov 26.
43. Lotz M, Wang HH, Cance W, Matthews J, Pories S. Epidermal growth fac-tor stimulation can substitute for c - Src overexpression in promoting breast carcinoma invasion. J Surg Res 2003; 109(2) : 123-9.
44. Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c - Src interactions in human breast tumor cells.
Mol Carcinog 1998; 21(4) : 261 -72.
45. Stover DR, Becker M, Liebetanz J, Lydon NB. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem 1995; 270(26): 15591 -7.
46. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000 ;77 : 25 -79.
47. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient ver-sus sustained extracellular signal - regulated kinase activation. Cell 1995 Jan 27;80(2):179-85.
48. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 139 -49.
49. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi - Galluzi C, Stork PJS. Expression of mitogen - activated protein ki-nase phosphatase - 1 in the early phases of human epithelial carcinogenesis. Am J Pathol, 1996; 149: 1553 -64.
50. Magi -Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodie-ci P, Wishnow K, Kaplan I, Stork PJ, Loda M. Mitogen -activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely re-lated to apoptosis. Lab Investig 1997; 76: 37 -51.
51. Oka H, Chatani Y, Boshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y,Kawaichi M, Kohno M, Yoshida 0. Constitutive activation of mitogen -ac-tivated protein ( MAP) kinases in human renal cell carcinoma Cancer Res 1995 ;55: 4182-87.
52. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T,Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N, Hori M. Ac-tivation of mitogen - activated protein kinases/extracellular signal - regula-ted kinases in human hepatocellular carcinoma. Hepatology 1998 ;27:951 -8.
53. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida 0. Shimada Y, Ari - i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41 -/43 - kDa mitogen - activated protein kinase signaling pathway in hu-
man tumors. Oncogene 1999; 18: 813 -22.
54. Gioeli D, Mandell JW, Petroni GR, Frierson HFJ, Weber MJ. Activation of mitogen - activated protein kinase associated with prostate cancer progres-sion. Cancer Res 1999;59: 279 -84.
55. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling: immunohistochemical lo-calization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998;153: 1411-23.
56. Gee J, Barroso A, Ellis I, Robertson J, Nicholson R. Biological and clini-cal associations of c - jun activation in human breast cancer. Int J Cancer 2000 ;89: 177-86.
57. Staley CA, Parikh NU, Gallick GE. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c - Src. CeU Growth Differ 1997 ;8(3) : 269 -74.
58. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and me-tastasis. J Pathol 1999 Nov; 189(3) :300 -8.
59. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000 Jan 20;57(1):5 - 15.
60. O'Connor CM, FitzGerald MX. Matrix metalloproteases and lung disease.Thorax 1994 Jun;49(6):602 -9.
61. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metallo-proteinases: biologic activity and clinical implications. J Clin Oncol 2000 Mar;18(5):1135-49.
62. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D,Kemp B, Lee JJ, Hong WK, Fidler U. Differential expression of E - cad-herin and type IV collagenase genes predicts outcome in patients with stage I non - small cell lung carcinoma. Clin Cancer Res 2000 Mar;6(3):790 -7.
63. Talbot DC, Brown PD. Experimental and clinical studies on the use of ma-trix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996 Dec;32A(14):2528-33.
64. Martinella - Catusse C, Nawrocki B, Gilles C, Birembaut P, Polette M. Matrix - metalloproteinases in bronchopulmonary carcinomas. Histol His-
topathol 1999 Jul;14(3) :839-43.
65. Ito H, Gardner - Thorpe J, Zinner MJ, Ashley SW, Whang EE. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003; 134:221-6.
66. Recchia I, Rucci N, Festuccia C, Bologna M, MacKay AR, Migliaccio S,Longo M, Susa M, Fabbro D, Teti A. Pyrrolopyrimidine c - Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003; 39:1927 - 35.
67. Verheijen JH, Nieuwenbroek NM, Beekman B, Hanemaaijer R, Verspaget HW, Ronday HK, Bakker AH. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and ma-trix metalloproteinase activity using modified pro - urokinase. Biochem J 1997 May 1 ;323 ( Pt 3) :603 -9.
68. Shiraga M, Yano S, Yamamoto A, Ogawa H, Goto H, Miki T, Miki K, Zhang H, Sone S. Organ heterogeneity of host - derived matrix metallopro-teinase expression and its involvement in multiple - organ metastasis by lung cancer cell lines. Cancer Res 2002 Oct 15;62(20) :5967 -73.
69. Albini A, Iwamoto Y, Kleinman H K, et al. A rapid in vitro assay for quan-titating the invasive potential of tumor cells. Cancer Res 1987; 47 ( 12) :3239-45.
70. Yano S, Nishioka Y, Izumi K, Tsuruo T, Tanaka T, Miyasaka M, Sone S.Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996; 67(2): 211 -7.
71. Liotta LA. Tumor invasion and metastases - - role of the extracellular ma-trix: Rhoads Memorial Award lecture. Cancer Res 1986 Jan;46(l) :1 -7.
72. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling.Trends Genet. 1990 Apr;6(4):121 -5.
73. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DR. Dis-tribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991 Nov 11 ;49(5) :666 -72.
74. Ylisirnio S, Hoyhtya M, Turpeenniemi - Hujanen T. Serum matrix metallo-proteinases - 2, - 9 and tissue inhibitors of metalloproteinases -1, - 2 in
lung cancer----TIMP -1 as a prognostic marker. Anticancer Res 2000Mar-Apr;20(2B):.1311-6.
75. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. Ex-pression of matrix metalloproteinase ( gelatinase) in Tl adenocarcinoma of the lung. Pathol Int 1997 Jul;47(7) :461 -9.
76. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72 - kilodalton gelatinase and tumor spread in non - small - cell lung carcinoma. J Natl Cancer Inst 1993 Apr 7; 85(7):574-8.
77. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expres-sion in tumor invasion. FASEB J 1999 May; 13(8) :781 -92.
78. Sato H, Kita M, Seiki M. v - Src activates the expression of 92 - kDa type IV collagenase gene through the AP -1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression in-dependent of that by inflammatory cytokines. J Biol Chem 1993 Nov 5; 268(31):23460-8.
79. Brunton VG, Ozanne BW, Paraskeva C, et al. A role for epidermal growth factor receptor, c - Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene 1997; 14(3) :283 -93.
80. Sone S, Shinohara T, Nishioka Y, Yano S. Symposium on molecular patho-genesis of respiratory diseases and its clinical implication. Molecular patho-genesis of lung cancer and its molecular targeted therapy. Intern Med 2001;40(2); 167-70.
81. Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogene-sis in non - small cell lung cancer, and therapeutics targeting related mole-cules. Cancer Sci 2003 Jun;94(6):479 -85.
82. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non - small - cell lung carcinoma: a pro-spective study. J Natl Cancer Inst 1997; 89: 881 -6.
83. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yama-da T, Hanaoka N, Inui K, Wada H. Evaluation of angiogenesis in non -
small cell lung cancer: comparison between anti - CD34 antibody and anti -CD105 antibody. Clin Cancer Res 2001; 7: 3410 -5.
84. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, Sculier JP. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta - analysis. Br J Cancer 2002; 87: 694 -701.
85. Folkman J, DAmore PA. Blood vessel formation: what is its molecular ba-sis? CeU 1996 Dec 27 ;87(7):1153-5.
86. Scappaticci FA. Mechanisms and future directions for angiogenesis - based cancer therapies. J Clin Oncol 2002; 20: 3906 -27.
87. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor;a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368 -80.
88. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. Vascular endothelial growth factor is asso-ciated with neovascularization and influences progression of non - small cell lung carcinoma. Clin Cancer Res 1997; 3: 861 -5.
89. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Vascu-lar endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 1999; 48: 396 -400.
90. Fleming RY, Ellis LM, Parikh NU, Iiu W, Staley CA, Gallick GE. Regu-lation of vascular endothelial growth factor expression in human colon carci-noma cells by activity of src kinase. Surgery 1997 Aug;122(2) :501 -7.
91. Munshi N, Groopman JE, Gill PS, Ganju RK. c -Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells. J Immunol 2000 Feb 1;164(3) :1169-74.
92. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998 Sep 18;94(6) :715 -25.
93. Cox G, Jones JL, Walker RA, Steward WP, OByrne KJ. Angiogenesis and non - small cell lung cancer. Lung Cancer 2000 Feb;27(2) :81 -100.
94. Mitzner W, Lee W, Georgakopoulos D, Wagner E. Angiogenesis in the mouse lung. Am J Pathol 2000 Jul; 157 (1):93 -101.
95.Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K. Broad antitumor and antiangiogenic activities of AG3340, a potent and se-lective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999 Jun 30;878:236 -70.
96. Aikawa H, Takahashi H, Fujimura S, Sato M, Endo C, Sakurada A, Kon-do T, Tanita T, Matsumura Y, Ono S, Saito Y, Sagawa M. Immunohisto- chemical study on tumor angiogenic factors in non - small cell lung cancer. Anticancer Res 1999 Sep -Oct;19(5B) :4305 -9.
97. Shibuya M. Structure and function of VEGF/VEGF - receptor system in-volved in angiogenesis. Cell Struct Funct 2001 Feb;26(l) :25 -35.
98. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-68.
99. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S and Tominaga T. Vascu-lar endothelial growth factor and platelet - derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast canc-er. Clin Cancer Res 1995 ;1: 961 -4.
100. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell pro-liferation in human epidermoid lung carcinoma. Br J Cancer 1996 Apr; 73 (7):931-4.
101. Boldrini L, Calcinai A, Silvestri V, Basolo F, Lucchi M, Mussi A, Ange-letti CA, Bevilacqua G, Fontanini G. Quantitation by competitive PCR as-say of vascular endothelial growth factor in non - small cell lung carcino-mas. Int J Oncol 1999 Jan;14(1) :161 -8.
102. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into